Improving Chronic Obstructive Pulmonary Disease Outcomes with Early Clinical and Biomedical Interventions

The online educational activity contains video and slides from the Allergy, Asthma, and Immunology Section‘s COPD Cluster Session held on July 30, 2016 during the National Medical Association’s 2016 Annual Convention and Scientific Assembly in Los Angeles, CA. This activity was supported in part by educational grants from AstraZeneca, GlaxoSmithKline, Merck & Co.

 

National Medical Association Annual Convention and Scientific Assembly, 2016

Physician Interdisciplinary Approaches to Improved Care Through Patient-Centered Diagnosis and Treatment

Improving Chronic Obstructive Pulmonary Disease Outcomes with Early Clinical and Biomedical Interventions

 

 

Chronic obstructive pulmonary disease (COPD), a common respiratory condition characterized by airflow limitation affects more than 5 percent of the population and is associated with high morbidity and mortality.  It is the third-ranked cause of death in the United States, killing more than 120,000 individuals each year.  As a consequence of its high prevalence and chronicity, COPD causes high resource utilization with frequent clinician office visits, frequent hospitalizations due to acute exacerbations, and the need for chronic.  In this presentation, The definition, clinical manifestations, diagnostic evaluation, and staging of COPD are discussed in this presentation.

 COPD Core Competencies:

  • • Patient-Centered Care                                    • Diagnostic and Treatment Performance Improvements       
  • • Physicians Interdisciplinary Teams
  • • Patient-Level Quality Improvements                • Utilization of Diagnostic Tools

Program Instructional Goal:

  1. Recognize updated GOLD Guidelines for the treatment of stable chronic obstructive pulmonary disease (COPD), include the concepts of symptoms and risks into the decision of therapy.
  2. Review of the concept of clinical phenotypes and how patients respond differently to available clinical and biomedical treatments.
  3. Define Asthma COPD overlap syndrome.
  4. Outline and identify patients that respond to specific pharmacological interventions.
  5. Review Alpha one antitrypsin deficiency and its relationship to the development of COPD.

Disclosures / Acknowledgement of Financial Support

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose any relevant financial relationships.  An individual has a relevant financial relationship if he or she (or spouse/partner) has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.  As an accredited provider balance, independence, objectivity, and scientific rigor must be demonstrated in all educational activities.

The following faculty presenters and planners/managers have stated that they do not have financial relationships or relationships to products or devices with any commercial interests related to the content of this activity during the past 12 months:

Charles U. Gbadouwey, M.D.

Chanda Nicole Holsey, DrPH, MPH

Kartik V. Shenoy, M.D.

Colin Syphax

 

Disclosures of Commercial Relationships

The following have listed the entities with whom they have relationships, not necessarily conflicting:  

Michael B. Foggs, M.D.

Consultant and Speaker:  AstraZeneca, GSK, Merck, Boehringer Ingelheim, Sunovion


Continuing Education Credits

The National Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  The National Medical Association designates this internet enduring activity for a maximum for 1 AMA PRA Category 1 Credit.  Physicians should claim credit commensurate with the extent of their participation in the activity.

Participants must achieve at least 80% correct in the post test evaluation to be awarded credit. 

Expiration

September 15, 2017

Disclaimer

The National Medical Association (NMA) and its staff and consultants, are not responsible for injury or illness resulting from the use of medications or modalities discussed during this educational activity. The NMA does not endorse the use of off-labeled medications. Speakers must identify off-labeled status of any pharmaceuticals mentioned in their lectures.




Courses

Improving Chronic Obstructive Pulmonary Disease Outcomes with Early Clinical and Biomedical Interventions

The online educational activity contains video and slides from the Allergy, Asthma, and Immunology Section‘s COPD Cluster Session held on July 30, 2016 during the National Medical Association’s 2016 Annual Convention and Scientific Assembly in Los Angeles, CA. This activity was supported in part by educational grants from AstraZeneca, GlaxoSmithKline, Merck & Co.

Publish Date: 09/15/2016
Number of Videos: 4